Amgen’s Sotorasib Updates Raise New Questions For KRAS Program

Lower Dose Being Tested Against Higher Dose Under FDA Review

 
• By Mandy Jackson
  
Stack of question marks on wood table
Amgen's Lumakras updates raised new questions about the KRAS G12C inhibitor • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapeutic Category